The Use of a Ultra-sound of the Lung to Diagnose Lung Diseases

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2011 by Echosense Ltd.
Sponsor:
Information provided by (Responsible Party):
Echosense Ltd.
ClinicalTrials.gov Identifier:
NCT01225367
First received: October 19, 2010
Last updated: June 24, 2014
Last verified: May 2011
  Purpose

The study is a prospective open evaluating study of Ultrasound/Doppler application to the chest cavity intended to detect and characterize pathologies of the pulmonary and cardio-vascular system.

The system is a noninvasive non-imaging device designated to monitor flow and movement velocity and display the data continuously.


Condition Intervention
Pulmonary Pathologies
Cardio-pulmonary Diseases
Device: ultrasound doppler monitoring

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Detection and Characterization of Cardio-pulmonary Patho-physiological States and Diseases by Ultrasound Transthoracic Doppler

Resource links provided by NLM:


Further study details as provided by Echosense Ltd.:

Primary Outcome Measures:
  • Diagnose specific pattern of LDS signals as Power and Velocity in pulmonary diseases in comparison to controls. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: August 2010
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
pulmonary doppler Device: ultrasound doppler monitoring
Regular noninvasive chest echo monitoring

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • Age 18y or older
  • patients who are clinically suspected of having a significant pulmonary or cardio-pulmonary disease
  • Patients with CHF
  • Patients with pulmonary hypertension
  • Patients with COPD
  • Patients with Asthma
  • Signed informed consent
  • Normal subjects

Exclusion Criteria:

  • Patients with unstable conditions: unstable angina, uncontrolled CHF, etc
  • Inability to assume a sitting or supine position
  • Patients with severe chest wall deformity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01225367

Contacts
Contact: Daniel Weiler-Ravell, MD +972-54 5322422 dani@echosense.co.il
Contact: Rachel Schatzberger, PhD +972- 4 -8500101 rachel@echosense.co.il

Locations
Israel
Elisha hospital Recruiting
Haifa, Israel, 31064
Contact: Daniel Weiler, MD    +972-54-5322422    dani@echosense.co.il   
Contact: Rachel Schatzberger, PhD    +972-4-8500101    rachel@echosense.co.il   
Sub-Investigator: Daniel Weiler, Dr         
Sponsors and Collaborators
Echosense Ltd.
Investigators
Principal Investigator: Moshe Person, MD Elisha Hospital
  More Information

No publications provided

Responsible Party: Echosense Ltd.
ClinicalTrials.gov Identifier: NCT01225367     History of Changes
Other Study ID Numbers: ES_DOP05
Study First Received: October 19, 2010
Last Updated: June 24, 2014
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Heart Disease
Respiratory Tract Diseases
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 22, 2014